SEARCH

MEDIA PACK

NEWS

Current Edition

immuno-oncology

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the …

13 December 2017 news immuno-oncology mesothelioma

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

SEARCH

MENU

Current Edition

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Journal for Clinical Studies